The use of an urticaria control test for the evaluation of omalizumab treatment response in patients diagnosed with chronic urticaria


Engin B. , Yucesoy S. N. , Askin O. , Kutlubay Z. , Serdaroglu S.

TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, cilt.54, sa.4, ss.143-147, 2020 (ESCI İndekslerine Giren Dergi) identifier

  • Cilt numarası: 54 Konu: 4
  • Basım Tarihi: 2020
  • Doi Numarası: 10.4274/turkderm.galenos.2020.06887
  • Dergi Adı: TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY
  • Sayfa Sayıları: ss.143-147

Özet

Background and Design: Urticaria is a very common skin disease which is characterized by itchy, erythematous and edematous plaques. Angioedema can also be seen in half of the cases in addition to skin findings. In most cases of chronic urticaria, the underlying factor is not known. Omalizumab, a recombinant human monoclonal immunoglobulin G (IgG) antibody against IgE, is a safe treatment option in chronic urticaria cases which are resistant to treatment with antihistamines. This study aimed to evaluate the treatment responses of chronic urticaria patients taking omalizumab treatment with an urticaria control test (UCT).